The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. (13th March 2021)

• Record Type: Journal Article
• Authors: Seferović, Petar M.; Vardas, Panagiotis; Jankowska, Ewa A.; Maggioni, Aldo P.; Timmis, Adam; Milinković, Ivan; Polovina, Marija; Gale, Chris P.; Lund, Lars H.; Lopatin, Yuri; Lainscak, Mitja; Savarese, Gianluigi; Huculeci, Radu; Kazakiewicz, Dzianis; Coats, Andrew J.S.
• Other Names: investigator.
• Is Part Of: European journal of heart failure. Volume 23:Number 6(2021)
• Page Start: 906
• Page End: 914
• Publication Date: 2021-03-13
• Subjects: Heart failure -- Epidemiology -- Incidence -- Prevalence -- Hospitalization -- HFA Atlas; Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.2143
• Languages: English
• ISSNs: 1388-9842

Abstract

Abstract : Aims: The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) developed the HFA Atlas to provide a contemporary description of heart failure (HF) epidemiology, resources, reimbursement of guideline‐directed medical therapy (GDMT) and activities of the National Heart Failure Societies (NHFS) in ESC member countries. Methods and results: The HFA Atlas survey was conducted in 2018–2019 in 42 ESC countries. The quality and completeness of source data varied across countries. The median incidence of HF was 3.20 [interquartile range (IQR) 2.66–4.17] cases per 1000 person‐years, ranging from ≤2 in Italy and Denmark to >6 in Germany. The median HF prevalence was 17.20 (IQR 14.30–21) cases per 1000 people, ranging from ≤12 in Greece and Spain to >30 in Lithuania and Germany. The median number of HF hospitalizations was 2671 (IQR 1771–4317) per million people annually, ranging from <1000 in Latvia and North Macedonia to >6000 in Romania, Germany and Norway. The median length of hospital stay for an admission with HF was 8.50 (IQR 7.38–10) days. Diagnostic and management resources for HF varied, with high‐income ESC member countries having substantially more resources compared with middle‐income countries. The median number of hospitals with dedicated HF centres was 1.16 (IQR 0.51–2.97) per million people, ranging from <0.10 in Russian Federation and Ukraine to >7 in Norway and Italy. Nearly all countries reported full or partial reimbursement of standard GDMT, except ivabradine and sacubitril/valsartan. Almost all countries reported having NHFS or working groups and nearly half had HF patient organizations. Conclusions: The first report from the HFA Atlas has shown considerable heterogeneity in HF disease burden, the resources available for its management and data quality across ESC member countries. The findings emphasize the need for a systematic approach to the capture of HF statistics so that inequalities and improvements in care may be quantified and addressed.